Menlo Park-Based Pacific Biosciences Files for $200 Million IPO

Menlo Park, Calif. -- Pacific Biosciences, a Menlo Park-based developer of tools for biological research, on Monday filed with the Securities and Exchange Commission (SEC) to raise up to $200 million in its initial public offering (IPO). The company has not yet released details such as the number of shares to be offered or their expected price range. It plans to trade on the Nasdaq under the symbol "PACB." The news comes two months after Pacific Biosciences received a $50 million investment from San Diego-based Gen-Probe as part of a larger partnership to co-develop integrated clinical diagnostics systems. The company's SMRT Platform is used by researchers to study the synthesis and regulation of DNA, RNA and protein.
http://www.pacificbiosciences.com/
http://www.sec.gov/Archives/edgar/data/1299130/000119312510189512/ds1.htm